During the past decade, Hematology Oncology Associates of Central New York-Auburn conducted 34 clinical trials. In the 10-year time frame, 34 clinical trials started and 17 clinical trials were completed, i.e. on average, 50% percent of trials that started reached the finish line to date. In the past 5 years, 18 clinical trials started and 12 clinical trials were completed. i.e. 66.7% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Hematology Oncology Associates of Central New York-Auburn" #1 sponsor was "National Cancer Institute (NCI)" with 25 trials, followed by "Alliance for Clinical Trials in Oncology" with 15 trials sponsored, "SWOG Cancer Research Network" with 5 trials sponsored, "ECOG-ACRIN Cancer Research Group" with 3 trials sponsored and "Eastern Cooperative Oncology Group" with 3 trials sponsored. Other sponsors include -4 different institutions and companies that sponsored additional 6 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Hematology Oncology Associates of Central New York-Auburn" #1 collaborator was "National Cancer Institute (NCI)" with 25 trials as a collaborator, "Canadian Cancer Trials Group" with 4 trials as a collaborator, "NRG Oncology" with 3 trials as a collaborator, "Bayer" with 1 trials as a collaborator and "Cancer Prevention Pharmaceuticals, Inc." with 1 trials as a collaborator. Other collaborators include -1 different institutions and companies that were collaborators in the rest 9 trials.

According to Clinical.Site data, the most researched conditions in "Hematology Oncology Associates of Central New York-Auburn" are "Invasive Breast Carcinoma" (5 trials), "Chronic Lymphocytic Leukemia" (4 trials), "Small Lymphocytic Lymphoma" (4 trials), "Anatomic Stage II Breast Cancer AJCC v8" (3 trials) and "Breast Cancer" (3 trials). Many other conditions were trialed in "Hematology Oncology Associates of Central New York-Auburn" in a lesser frequency.

Most popular intervention types in "Hematology Oncology Associates of Central New York-Auburn" are "Other" (41 trials), "Drug" (38 trials), "Biological" (22 trials), "Procedure" (14 trials) and "Dietary Supplement" (2 trials). Other intervention types were less common.

The name of intervention was led by "Quality-of-Life Assessment" (24 trials), "Laboratory Biomarker Analysis" (12 trials), "Questionnaire Administration" (11 trials), "Biospecimen Collection" (9 trials) and "Computed Tomography" (8 trials). Other intervention names were less common.

The vast majority of trials in "Hematology Oncology Associates of Central New York-Auburn" are 44 trials for "All" genders and 6 trials for "Female" genders.

Currently, there are NaN active trials in "Hematology Oncology Associates of Central New York-Auburn". undefined are not yet recruiting, 16 are recruiting, 22 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 8 completed trials in Hematology Oncology Associates of Central New York-Auburn, 1 suspended trials, and 3 terminated clinical trials to date.

Out of the total trials that were conducted in Hematology Oncology Associates of Central New York-Auburn, 1 "Phase 1" clinical trials were conducted, 13 "Phase 2" clinical trials and 35 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 2 trials that are defined as “Not Applicable".